The case for & against
Bull & Bear analysis
Bullish
DaVita Inc. (NYSE: DVA) is a leading provider of kidney care services, primarily focusing on outpatient dialysis treatment and related services for patients with chronic kidney failure. The company operates a robust network of dialysis centers and emphasizes integrated kidney care models aimed at enhancing clinical outcomes and operational efficiencies. The business is at the forefront of trends toward value-based care in the healthcare sector, strategically leveraging technology to optimize patient care delivery.
Bull says
- ↑Q4 2025 adj. operating income $586M and EPS $3.40
- ↑2026 EPS guidance raised to $14.10–$15.20 range
- ↑Integrated Kidney Care to add incremental $20M operating income in 2026
- ↑13M shares repurchased for $1.8B; free cash flow $1–1.25B in 2025
- ↑Investing in AI and tech to boost efficiency and patient outcomes
- ↑High earnings yield and positive momentum support valuation
Bear says
- ↓Q4 2025 treatment volumes fell 1.1% YoY
- ↓Patient care cost per treatment rose ~5–6%, squeezing margins
- ↓Expiration of premium tax credits to cost ~$40M in 2026
- ↓Leverage elevated and elevated short interest signals investor wariness
- ↓Weak growth and muted profitability factors raise sustainability concerns
- ↓Regulatory uncertainty around drug therapies adds policy risk
Investment themes with DVA
Buybacks↑ +0.48%
Companies repurchasing their own shares
C · JCI · WFC
Health Care Providers↓ -0.61%
UNH · CVS · HCA
Demographics: Elderly Care↓ -0.26%
Services and products for aging population
UCB.BR · JNJ · AZN
Earnings Call · Q4 2025 · Mgmt. Guidance
Updated 02-03-2026neutral
Transcript signals
Bull points
- As a result, we're well positioned for 2026 and beyond, with opportunities to deliver clinical and financial results consistent with our longstanding track record and guidance.
- This quarter, I want to spotlight the clinical results achieved in our integrated kidney care, or IKC, programs. Patients managed under IKC models consistently achieve better outcomes than the broader dialysis population.
- Our IKC patients are 35% more likely to start dialysis with a permanent vascular access, resulting in a better patient experience and costs that are three times lower during the first 180 days of dialysis.
Bear points
- As anticipated, revenue per treatment accelerated in the quarter alongside strength in IKC. This was partially offset by higher than expected health benefit costs.
- We're managing two near-term financial headwinds. continued pressure on treatment growth driven by elevated mortality, and the revenue per treatment impact from the expiration of enhanced premium tax credits.
- treatments declined about 20 basis points versus the fourth quarter of 2024.
Read full transcript analysis ›